بررسی تأثیر درازمدت اریتروپوئتین در کاهش آسیب های ناشی از ایسکمی و ریپرفوزیون حین عمل بایپس عروق کرونری

Abstract Background and purpose: Recent studies showed that erythropoietin (EPO) despite having role in hematopoiesis, has non-hematopoietic tissue protective effects on ischemia-reperfusion injury. In this study we evaluated the effects of erythropoietin on reducing ischemia-reperfusion injuries after coronary artery bypass graft surgery (CABG). Materials and methods: 60 patients that was candidate for elective CABG randomly divided into two groups, EPO and control group. Patients in EPO group received IV infusion of EPO (700 IU/kg), at the start of reperfusion after aorta cross clamp. Cardiac markers: Troponin I and Creatine kinase MB (CKMB) assessed 8hours after CABG surgery. Also echocardiography was performed in all patients 6month after surgery. Results: Troponin I level had no difference in EPO and control group (P=0.30). CKMB level in EPO group was higher than control group (P=0.004). After 6month from surgery, Ejection fraction (EF) in EPO group was higher than control group but differences wasn’t significant (P=0.46). But Left ventricle end systolic diameter (P=0.017) and also Left ventricle end diastolic diameter (P= 0.04) in EPO group were significantly lesser than control group 6month after surgery Conclusion: in this study the administration of erythropoietin was associated with reduction in ischemia-reperfusion injuries by improving ventricular function, and also with reduction in myocardial remodeling and decrease in Left ventricle end systolic diameter and Left ventricle end diastolic diameter